Association between funding sources and the scope and outcomes of cardiovascular clinical trials: A systematic review

被引：7

作者：

Vaduganathan, Muthiah ^{[1
,2
]}

Samman-Tahhan, Ayman ^{[3
]}

Patel, Ravi B. ^{[4
]}

Kelkar, Anita ^{[3
]}

Papadimitriou, Lampros ^{[5
]}

Georgiopoulou, Vasiliki V. ^{[3
]}

Greene, Stephen J. ^{[6
]}

Kalogeropoulos, Andreas P. ^{[3
]}

Peterson, Eric ^{[6
]}

Fonarow, Gregg C. ^{[7
]}

Gheorghiade, Mihai ^{[8
]}

Butler, Javed ^{[5
]}

机构：

[1] Brigham & Womens Hosp, Heart & Vasc Ctr, 75 Francis St, Boston, MA 02115 USA

[2] Harvard Med Sch, 75 Francis St, Boston, MA 02115 USA

[3] Emory Univ, Div Cardiol, Atlanta, GA 30322 USA

[4] Northwestern Univ, Northwestern Mem Hosp, Feinberg Sch Med, Div Cardiol,Bluhm Cardiovasc Inst, Chicago, IL 60611 USA

[5] SUNY Stony Brook, Div Cardiol, Stony Brook, NY 11794 USA

[6] Duke Univ, Med Ctr, Duke Clin Res Inst, Durham, NC USA

[7] Univ Calif Los Angeles, Div Cardiol, Los Angeles, CA USA

[8] Northwestern Univ, Feinberg Sch Med, Ctr Cardiovasc Innovat, Chicago, IL 60611 USA

来源：

INTERNATIONAL JOURNAL OF CARDIOLOGY | 2017年 / 230卷

关键词：

Cardiovascular; Clinical trials; Funding source; Outcomes; Trial design; CLINICALTRIALS.GOV; TRENDS;

D O I：

10.1016/j.ijcard.2016.12.119

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

[No abstract available]

引用

页码：301 / 303

页数：3

共 10 条

[1] Association of funding and conclusions in randomized drug trials - A reflection of treatment effect or adverse events?
Als-Nielsen, B
Chen, WD
Gluud, C
Kjaergard, LL
[J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 290 (07): : 921 - 928
[2] Bhandari M, 2004, CAN MED ASSOC J, V170, P477
[3] Trends in characteristics of cardiovascular clinical trials 2001-2012
Butler, Javed
Tahhan, Ayman Samman
Georgiopoulou, Vasiliki V.
Kelkar, Anita
Lee, Michael
Khan, Bilal
Peterson, Eric
Fonarow, Gregg C.
Kalogeropoulos, Andreas P.
Gheorghiade, Mihai
[J]. AMERICAN HEART JOURNAL, 2015, 170 (02) : 263 - U99
[4] Relationship Between Clinical Trial Site Enrollment With Participant Characteristics, Protocol Completion, and Outcomes Insights From the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) Trial
Butler, Javed
Subacius, Haris
Vaduganathan, Muthiah
Fonarow, Gregg C.
Ambrosy, Andrew P.
Konstam, Marvin A.
Maggioni, Aldo
Mentz, Robert J.
Swedberg, Karl
Zannad, Faiez
Gheorghiade, Mihai
[J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2013, 61 (05) : 571 - 579
[5] Characteristics of Clinical Trials Registered in ClinicalTrials.gov, 2007-2010
Califf, Robert M.
Zarin, Deborah A.
Kramer, Judith M.
Sherman, Rachel E.
Aberle, Laura H.
Tasneem, Asba
[J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2012, 307 (17): : 1838 - 1847
[6] Industry funding of clinical trials: Benefit or bias?
Chopra, SS
[J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 290 (01): : 113 - 114
[7] Trends in National Institutes of Health Funding for Clinical Trials Registered in ClinicalTrials.gov
Ehrhardt, Stephan
Appel, Lawrence J.
Meinert, Curtis L.
[J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2015, 314 (23): : 2566 - 2567
[8] Publication bias in clinical trials due to statistical significance or direction of trial results
Hopewell, Sally
Loudon, Kirsty
Clarke, Mike J.
Oxman, Andrew D.
Dickersin, Kay
[J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2009, (01):
[9] Pharmaceutical industry sponsorship and research outcome and quality: systematic review
Lexchin, J
Bero, LA
Djulbegovic, B
Clark, O
[J]. BMJ-BRITISH MEDICAL JOURNAL, 2003, 326 (7400): : 1167 - 1170B
[10] Reported outcomes in major cardiovascular clinical trials funded by for-profit and not-for-profit organizations: 2000-2005
Ridker, PM
Torres, J
[J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 295 (19): : 2270 - 2274

← 1 →